Precision Synthesis of Iron Oxide Nanoparticles and Their Use as Contrast Agents

2012 ◽  
pp. 87-91
Author(s):  
Jan Niehaus ◽  
Sören Becker ◽  
Christian Schmidtke ◽  
Katja Werner ◽  
Horst Weller
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Oxide Nanoparticles ◽  
Precision Synthesis

scholarly journals Iron Oxide Nanoparticles as Theranostic Agents in Cancer Immunotherapy

Nanomaterials ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1950
Author(s):  
Rossella Canese ◽  
Federica Vurro ◽  
Pasquina Marzola
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Cancer Immunotherapy ◽  
Iron Oxide Nanoparticles ◽  
Imaging Techniques ◽  
Macrophage Polarization ◽  
Mri Contrast Agents ◽  
Oxide Nanoparticles ◽  
Diagnostic Potential ◽  
Theranostic Agents

Starting from the mid-1990s, several iron oxide nanoparticles (NPs) were developed as MRI contrast agents. Since their sizes fall in the tenths of a nanometer range, after i.v. injection these NPs are preferentially captured by the reticuloendothelial system of the liver. They have therefore been proposed as liver-specific contrast agents. Even though their unfavorable cost/benefit ratio has led to their withdrawal from the market, innovative applications have recently prompted a renewal of interest in these NPs. One important and innovative application is as diagnostic agents in cancer immunotherapy, thanks to their ability to track tumor-associated macrophages (TAMs) in vivo. It is worth noting that iron oxide NPs may also have a therapeutic role, given their ability to alter macrophage polarization. This review is devoted to the most recent advances in applications of iron oxide NPs in tumor diagnosis and therapy. The intrinsic therapeutic effect of these NPs on tumor growth, their capability to alter macrophage polarization and their diagnostic potential are examined. Innovative strategies for NP-based drug delivery in tumors (e.g., magnetic resonance targeting) will also be described. Finally, the review looks at their role as tracers for innovative, and very promising, imaging techniques (magnetic particle imaging-MPI).

Succinylated heparin monolayer coating vastly increases superparamagnetic iron oxide nanoparticle T2 proton relaxivity

Nanoscale ◽  
2019 ◽  
Vol 11 (27) ◽  
pp. 12905-12914 ◽  
Author(s):  
Manman Xie ◽  
Shijia Liu ◽  
Christopher J. Butch ◽  
Shaowei Liu ◽  
Ziyang Wang ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Superparamagnetic Iron Oxide ◽  
Iron Oxide Nanoparticle ◽  
Oxide Nanoparticles ◽  
Clinical Use ◽  
History Of ◽  
Oxide Nanoparticle ◽  
Superparamagnetic Iron Oxide Nanoparticle

Superparamagnetic iron oxide nanoparticles (SPIONs) have a history of clinical use as contrast agents in T2 weighted MRI, though relatively low T2 relaxivity has caused them to fall out of favor as new faster MRI techniques have gained prominence.

NMR-based metabonomic analysis of MnO-embedded iron oxide nanoparticles as potential dual-modal contrast agents

2014 ◽  
Vol 16 (5) ◽  
Author(s):  
Jinquan Li ◽  
Zijian Zhou ◽  
Jianghua Feng ◽  
Shuhui Cai ◽  
Jinhao Gao ◽  
...  
Keyword(s):  
Iron Oxide ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Oxide Nanoparticles

The Evolution of Iron Oxide Nanoparticles as MRI Contrast Agents

MRS Advances ◽  
2020 ◽  
Vol 5 (42) ◽  
pp. 2157-2168
Author(s):  
Aileen O'Shea ◽  
Anushri Parakh ◽  
Rita Maria Lahoud ◽  
Sandeep Hedgire ◽  
Mukesh G Harisinghani
Keyword(s):  
Iron Oxide ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Imaging Techniques ◽  
Mri Contrast Agents ◽  
Oxide Nanoparticles ◽  
Clinical Imaging ◽  
Iron Storage ◽  
Inflammatory Conditions

AbstractWhile the use of iron oxide nanoparticles as magnetic resonance contrast agents for clinical imaging is established, they are more recently experiencing renewed interest as alternatives to gadolinium-based contrast agents. Ultra-small iron oxide nanoparticles have unique pharmacokinetics, metabolic and imaging properties. These properties have led to improved techniques for imaging a variety of vascular, oncologic and inflammatory conditions with iron oxide nanoparticles. Current research efforts are aimed at harnessing the characteristics of these nanoparticles to advance magnetic resonance imaging techniques and explore new therapeutic potentials. While there are some limitations to the use of iron oxide nanoparticles, including allergies to parenteral iron and iron storage disorders, the practicable applications for these agents will continue to expand. The purpose of this review is to provide a brief overview of the history and synthesis of iron oxide nanoparticles, their current applications in clinical imaging and their prospective clinical applications.

Synthesis of gadolinium oxide nanodisks and gadolinium doped iron oxide nanoparticles for MR contrast agents

2017 ◽  
Vol 5 (3) ◽  
pp. 418-422 ◽  
Author(s):  
Gurvinder Singh ◽  
Birgitte Hjelmeland McDonagh ◽  
Sjoerd Hak ◽  
Davide Peddis ◽  
Sulalit Bandopadhyay ◽  
...  
Keyword(s):  
Thermal Decomposition ◽  
Iron Oxide ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Gadolinium Oxide ◽  
Oxide Nanoparticles ◽  
Mr Contrast Agents

Herein, we report the synthesis of differently sized gadolinium oxide nanodisks and gadolinium doped iron oxide spherical and cubic nanoparticles through the thermal decomposition of an oleate precursor.

scholarly journals Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

Inorganics ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 28 ◽  
Author(s):  
Irene Fernández-Barahona ◽  
María Muñoz-Hernando ◽  
Jesus Ruiz-Cabello ◽  
Fernando Herranz ◽  
Juan Pellico
Keyword(s):  
Magnetic Resonance Imaging ◽  
Iron Oxide ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
Positive Contrast ◽  
Oxide Nanoparticles ◽  
Resonance Imaging ◽  
The Past ◽  
T1 Contrast

Iron oxide nanoparticles have been extensively utilised as negative (T2) contrast agents in magnetic resonance imaging. In the past few years, researchers have also exploited their application as positive (T1) contrast agents to overcome the limitation of traditional Gd3+ contrast agents. To provide T1 contrast, these particles must present certain physicochemical properties with control over the size, morphology and surface of the particles. In this review, we summarise the reported T1 iron oxide nanoparticles and critically revise their properties, synthetic protocols and application, not only in MRI but also in multimodal imaging. In addition, we briefly summarise the most important nanoparticulate Gd and Mn agents to evaluate whether T1 iron oxide nanoparticles can reach Gd/Mn contrast capabilities.

scholarly journals Targeting of cell death and neuroinflammation with peptide-linked iron oxide nanoparticles and Gd-DTPA in a mouse model of Parkinson's disease

2015 ◽  
Vol 2 (1) ◽  
pp. 13 ◽  
Author(s):  
Coralie Sclavons ◽  
Sébastien Boutry ◽  
Sophie Laurent ◽  
Luce Vander Elst ◽  
Robert N Muller
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Iron Oxide ◽  
Contrast Agents ◽  
Iron Oxide Nanoparticles ◽  
In Vivo Studies ◽  
Oxide Nanoparticles ◽  
Necrosis Factor Alpha ◽  
Apoptosis And Inflammation

Parkinson’s disease (PD) is one of the most common neurodegenerative disease and remains difficult to diagnose by conventional methods of early detection. It is characterized by the apoptotic loss of dopaminergic neurons (DN) and a neuroinflammation mainly located in the ventral midbrain (VM). The aim of this work is to study new vectorized contrast agents for magnetic resonance imaging (MRI) detection of PD injured areas by targeting apoptosis and inflammation. Two peptides selected by phage display were used for the experiments: R826 peptide, selected for its affinity for the phosphatidylserine (PS) exposed at the external surface of apoptotic cells, and 2C peptide, selected for its affinity for TNF-α (tumor necrosis factor alpha), one of the most abundant cytokines secreted during inflammation. These peptides were grafted to pegylated iron oxide nanoparticles (PEG-USPIO) and gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) for in vitro and in vivo studies, respectively. PD was simulated on mice with the MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) neurotoxin and its active metabolite MPP+ (1-methyl-4-phenylpyridinium) for in vitro studies. The results showed that PEG-USPIO-R826 and PEG-USPIO-2C enabled the detection of apoptosis and inflammation, respectively, on MPP+-treated culture cells. PEG-USPIO-2C also allowed detection of inflammation on histological brain sections of MPTP-treated mice. The 2C peptide grafted to Gd-DTPA showed encouraging results in MRI detection of injured brain areas in MPTP-treated mice. These observations suggest that a targeting of damaged cells and injured areas by these new specific contrast agents occurs, offering a new tool for early diagnosis of neurodegenerative disorders like PD by MRI. 

Sign in / Sign up

Export Citation Format

Share Document